Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV-MAG + IL-12 plasmid DNA
- Development stage
- Unknown
- Lead developer
- Aurobindo Pharma
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
HIV-MAG + IL-12 plasmid DNA is a therapeutic DNA vaccine candidate designed to treat HIV-1 infection. Developed by Profectus Biosciences in collaboration with Ichor Medical Systems and the National Institute of Allergy and Infectious Diseases (NIAID), the vaccine consists of the HIV-MAG DNA plasmid, which encodes multiple HIV-1 antigens including Gag, Pol, Env, Nef, Tat, and Vif. It is co-administered with an optional plasmid DNA adjuvant, GENEVAX IL-12-4532, which encodes the p35 and p40 subunits of human interleukin-12 (IL-12) to enhance cellular immune responses. The vaccine is delivered via intramuscular injection followed by electroporation using Ichor's TriGrid Delivery System, a technology that uses brief electrical pulses to facilitate the entry of the DNA into host cells, thereby improving the magnitude and quality of the resulting T-cell mediated immune response.
- Brand names
- TriGrid
- Other names
- HIV-MAG DNA vaccineIL-12 plasmid adjuvantIL12 plasmid adjuvantIL 12 plasmid adjuvantpIL-12pIL12pIL 12HIV-MAG/pIL-12
02
Targets
Env (HIV-1 envelope glycoprotein)Gag (HIV-1 Gag polyprotein)Nef (HIV-1 Nef)Pol (HIV-1 Pol polyprotein)Tat (HIV-1 Tat)Vif (HIV-1 Vif)IL-12R (Interleukin-12 receptor)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)Human immunodeficiency virus type 1 reverse transcriptaseIL12 (Interleukin-12)
Beyond the preview
Go deeper on HIV-MAG + IL-12 plasmid DNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV-MAG + IL-12 plasmid DNA.